Tm Bioscience and Resurrection Medical Center, US National Science Foundation, Iconix Pharmaceuticals and Brigham and Women s Hospital, Tecan and Invitrogen, and Broad Institute and Affymetrix | GenomeWeb

Tm Bioscience Signs Supply deal with Resurrection Medical Center

Resurrection Medical Center will use Toronto, Canada-based Tm Bioscience’s Tag-It mutation detection tests to perform its genetic assays, Tm said this week in a statement.

Tm’s US-based sales force is now “well entrenched” with the larger labs and hospitals, said Greg Hines, president and CEO of Tm Bioscience. “We anticipate [Tm] will ultimately perform the majority of genetic testing as this industry matures,” he added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.